Perspective, Jtsdt Vol: 14 Issue: 1

Parkinson's disease and Psychological Health: Addressing Depression, Anxiety, and Cognitive Decline

Emma Clark^*

Department of Experimental Psychology, Brightwood Institute of Psychology, United States

*Corresponding Author: Emma Clark
Department of Experimental Psychology, Brightwood Institute of Psychology, United States
E-mail: emma.clark@brightwoodpsy.edu

Received: 10-Feb-2025, Manuscript No. JTSDT-25-161134;
Editor assigned: 11-Feb-2025, PreQC No. JTSDT-25-161134 (PQ);
Reviewed: 23-Feb-2025, QC No. JTSDT-25-161134;
Revised: 25-Feb-2025, Manuscript No. JTSDT-25-161134 (R);
Published: 28-Feb-2025, DOI:10.4172/2324-8947.100443

Citation: Clark E (2025) Parkinson’s disease and Psychological Health: Addressing Depression, Anxiety, and Cognitive Decline. J Trauma Stress Disor Treat 14(1):443

Copyright: © 2025 Clark E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Introduction

Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder that primarily affects movement, causing tremors, stiffness, slowness, and balance problems. While the motor symptoms are often the most visible and well-known, Parkinson's disease has a profound psychological impact as well. Psychological health is frequently overlooked in PD, even though depression, anxiety, and cognitive decline are prevalent among patients. These psychological issues can significantly affect quality of life and complicate the management of the disease, leading to a need for integrated care that addresses both the motor and non-motor symptoms of PD [1].

This article explores the psychological impact of Parkinson’s disease, focusing on depression, anxiety, and cognitive decline, and offers strategies for addressing these issues to improve the overall well-being of patients. Depression is one of the most common psychiatric disorders associated with Parkinson’s disease. Research indicates that up to 50% of people with PD experience depression at some point in their illness, which is much higher than the general population rate of approximately 10-20% [2]

Several factors contribute to the high incidence of depression in Parkinson’s disease. First, the neurodegenerative process of PD involves the loss of dopamine-producing neurons, which plays a key role in regulating mood. Moreover, the physical challenges of living with PD, including mobility issues and dependence on others, can exacerbate feelings of isolation, helplessness, and frustration, contributing to the onset or worsening of depression [3].

Treatment for depression in PD typically involves a combination of pharmacological and psychological interventions. Antidepressant medications, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), are often prescribed. However, these medications may not always be effective, and side effects such as worsening motor symptoms or orthostatic hypotension can be problematic.  Psychological interventions such as cognitive-behavioral therapy (CBT) have shown effectiveness in treating depression in PD patients. CBT helps patients identify and challenge negative thought patterns and develop coping strategies to manage emotional distress [4].

Anxiety is another prevalent psychological issue in people with Parkinson's disease. Estimates suggest that approximately 30-40% of individuals with PD suffer from anxiety disorders. Anxiety in PD can present as generalized anxiety disorder (GAD), panic attacks, social anxiety, or specific phobias. The symptoms of anxiety can exacerbate motor symptoms, making it difficult for individuals to function optimally in daily life. The causes of anxiety in PD are multifactorial. Dopamine deficiency is implicated in both motor and non-motor symptoms, including anxiety. Additionally, the uncertainty about disease progression, the fear of becoming more dependent, and concerns about the impact of symptoms on social and occupational roles contribute to heightened anxiety [5].

Pharmacological treatment for anxiety in Parkinson’s disease often involves the use of medications such as SSRIs, benzodiazepines, or buspirone. However, benzodiazepines are typically prescribed cautiously due to the risk of sedation, falls, and worsening motor symptoms. Psychotherapy, particularly cognitive-behavioral therapy (CBT), is highly effective for managing anxiety in PD. CBT can help patients identify the sources of their anxiety, challenge irrational fears, and develop coping strategies to reduce anxiety levels. Relaxation techniques such as progressive muscle relaxation, deep breathing, and mindfulness meditation have also shown efficacy in managing anxiety in Parkinson’s disease [6].

Cognitive decline is a common feature of Parkinson’s disease, especially as the disease progresses. Up to 30-40% of people with Parkinson’s will develop Parkinson’s disease dementia (PDD), characterized by significant cognitive impairment that affects attention, executive function, memory, and language. Cognitive decline in Parkinson’s disease is different from Alzheimer’s disease in that it primarily affects executive function, such as planning, problem-solving, and impulse control [7].

The progression of cognitive decline in PD is linked to the degeneration of various brain structures, particularly the frontal cortex and the basal ganglia. Additionally, the buildup of abnormal protein aggregates, such as alpha-synuclein, is believed to play a role in cognitive dysfunction. These cognitive difficulties can lead to increased dependence on caregivers, poorer quality of life, and difficulties with social and occupational functioning. Cognitive decline in Parkinson’s disease is challenging to manage, but early detection and intervention can slow its progression. Medications such as cholinesterase inhibitors (donepezil, rivastigmine) and glutamate antagonists (memantine) are sometimes used to treat cognitive symptoms in PD, though their effectiveness can vary [8].

Non-pharmacological interventions such as cognitive training and rehabilitation therapy can also be beneficial. These interventions aim to strengthen cognitive functioning and improve executive abilities through structured activities that challenge memory, attention, and problem-solving skills. Maintaining a structured routine and engaging in mentally stimulating activities such as reading, puzzles, and social interaction can help preserve cognitive function. Furthermore, addressing the broader psychosocial aspects of cognitive decline is essential. Family members and caregivers should be educated about cognitive changes in PD, which can enhance their ability to support the patient and reduce caregiver stress [9].

Given the complex interplay between physical, cognitive, and emotional symptoms in Parkinson's disease, a holistic approach to care is crucial. Treatment strategies should not focus solely on motor symptoms but should also address the psychological health of patients. Healthcare providers should regularly screen for depression, anxiety, and cognitive decline, incorporating psychological interventions alongside pharmacological treatment. Multidisciplinary care involving neurologists, psychiatrists, psychologists, physical therapists, and occupational therapists can provide a comprehensive treatment plan that targets the various aspects of Parkinson’s disease [10].

Conclusion

Parkinson’s disease presents a range of challenges for individuals, not only in terms of motor symptoms but also in the realm of psychological health. Depression, anxiety, and cognitive decline are common and often debilitating consequences of PD that can significantly affect a person’s quality of life. Addressing these issues requires a comprehensive and integrated approach that combines medication, psychological therapy, and support interventions. By treating both the motor and non-motor symptoms of Parkinson’s disease, healthcare providers can enhance the overall well-being of individuals with PD and improve their ability to manage the disease.

References

1. Fredericks D, Norton JC, Atchison C, Schoenhaus R, Pill MW. Parkinson’s disease and Parkinson’s disease psychosis: a perspective on the challenges, treatments, and economic burden. Am J Manag Care. 2017;23(5 Suppl):S83-92.

Indexed at, Google Scholar

2. Dissanayaka NN, Sellbach A, Matheson S, O'Sullivan JD, Silburn PA. Anxiety disorders in Parkinson's disease: prevalence and risk factors. Movement Disorder. 2010;25(7):838-45.

Indexed at, Google Scholar, Cross Ref

3. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. Jama. 2014;311(16):1670-83.

Indexed at, Google Scholar, Cross Ref

4. Bartzokis G. Neuroglialpharmacology: white matter pathophysiologies and psychiatric treatments. Front Biosci. 2011;16:2695-733.

Indexed at, Google Scholar, Cross Ref

5. Aarsland D, Kramberger MG. Neuropsychiatric symptoms in Parkinson’s disease. J Parkinsons Dis. 2015;5(3):659-67.

Indexed at, Google Scholar, Cross Ref

6. Tkaczynska Z. Kognitive Mechanismen der Blasenschwäche bei Morbus Parkinson .

Indexed at, Google Scholar, Cross Ref

7. Moretti R, Caruso P. The controversial role of homocysteine in neurology: from labs to clinical practice. Int J Mol Sci. 2019;20(1):231.

Indexed at, Google Scholar, Cross Ref

8. Galet B. Validating Gpr88 as a new therapeutic target in models of the neuropsychiatric symptoms of Parkinson's Disease .

Google Scholar

9. Broen MP, Narayen NE, Kuijf ML, Dissanayaka NN, Leentjens AF. Prevalence of anxiety in Parkinson's disease: a systematic review and meta-analysis. Movement Disorder. 2016;31(8):1125-33.

Indexed at, Google Scholar, Cross Ref

10. Hou JG, Lai EC. Non-motor symptoms of Parkinson's disease. Int J Gerontol. 2007;1(2):53-64.

Indexed at, Google Scholar, Cross Ref